Lutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study.

Humans Pilot Projects Male Salivary Gland Neoplasms / drug therapy Middle Aged Lutetium / therapeutic use Prospective Studies Aged Female Positron Emission Tomography Computed Tomography Radioisotopes / therapeutic use Neoplasm Recurrence, Local Carcinoma, Adenoid Cystic / drug therapy Carcinoma, Ductal / drug therapy Radiopharmaceuticals / therapeutic use Adult Antigens, Surface Glutamate Carboxypeptidase II
(177)Lu-PSMA therapy Adenoid cystic carcinoma Prostate-specific membrane antigen Salivary duct carcinoma Salivary gland cancer

Journal

Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395

Informations de publication

Date de publication:
2024
Historique:
received: 29 05 2024
accepted: 22 07 2024
medline: 23 9 2024
pubmed: 23 9 2024
entrez: 23 9 2024
Statut: epublish

Résumé

There is an urgent need for novel systemic therapies for recurrent/systemic salivary gland cancer, as current treatment options are scarce. [

Identifiants

DOI: 10.7150/thno.99035 PMID: 39310108 PMC: PMC11413786
pubmed: 39310108
doi: 10.7150/thno.99035
pii: thnov14p5388
pmc: PMC11413786
doi:

Substances chimiques

Lutetium 5H0DOZ21UJ
Radioisotopes 0
Lutetium-177 BRH40Y9V1Q
Radiopharmaceuticals 0
FOLH1 protein, human EC 3.4.17.21
Antigens, Surface 0
Glutamate Carboxypeptidase II EC 3.4.17.21

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5388-5399

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: NvR, MU, CD, SP, BP, AvEvG, MK, MK: nothing to declare. JN: has received research grants from ABX and Novartis, and has received consulting and teaching fees from ITM, POINT biopharma, CURIUM, Novartis and Bayer. CvH: has been member of advisory boards for Bayer, Bristol-Myers Squibb, Elevar, Ipsen, MSD and Regeneron, and has received research grants from Astra Zeneca, Bristol-Myers Squibb, MSD, Merck, Ipsen, Novartis and Sanofi.

Auteurs

Niels J van Ruitenbeek (NJ)

Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Maike J M Uijen (MJM)

Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Chantal M L Driessen (CML)

Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Steffie M B Peters (SMB)

Department of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Bastiaan M Privé (BM)

Department of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Adriana C H van Engen-van Grunsven (ACH)

Department of Pathology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Mark W Konijnenberg (MW)

Department of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

Martin Gotthardt (M)

Department of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

James Nagarajah (J)

Department of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Roentgeninstitut Duesseldorf, Duesseldorf, Germany.

Carla M L van Herpen (CML)

Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Projets pilotes › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Maladies du système stomatognathique › Maladies de la bouche › Maladies de la glande salivaire › Tumeurs des glandes salivaires › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Terres rares › Lanthanides › Lutétium › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Produits chimiques inorganiques › Isotopes › Radio-isotopes › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Carcinome adénoïde kystique › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Tumeurs canalaires, lobulaires et médullaires › Carcinome canalaire › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Radiopharmaceutiques › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes de surface › Lutetium-177-PSMA therapy for...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › Metalloproteases › Metalloexopeptidases › Glutamate carboxypeptidase II › Lutetium-177-PSMA therapy for...